Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimensNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.…
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA…
Why Weight Loss Feels Impossible After 35 NEW YORK CITY, NY / ACCESS Newswire / August 31, 2025 / For…
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc.…
Guideline Emphasis on Earlier Treatment to Reduce Health, Dementia Risks Boosts Urgency to Keep Closer Watch on Blood Pressure OMRON…
New digital health network available January 1, 2026, for self-funded employers in Washington and Alaska MOUNTLAKE TERRACE, Wash., Aug. 19,…
90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed…
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)…
Holistic engagement programs offer healthcare organizations a scalable solution to support women and families in managing their physical, mental, and…
New York State Department of Health (NYSDOH) clinical laboratory permit facilitates Q3 2025 launch of the FDA-cleared PreClara™ Ratio (sFlt-1/PlGF)…